Skip to main content
Premium Trial:

Request an Annual Quote

Coffee, Anyone?


A new study published in the Journal of the National Cancer Institute adds to the growing body of evidence that says coffee is good for you, reports the Boston Globe's Deborah Kotz. The study shows that drinking "copious amounts" of coffee may reduce a man's risk of dying from prostate cancer, Kotz says. Study participants who drank one to three cups a day had a 30 percent lower risk of prostate cancer, and those who drank six cups a day had a 60 percent lower risk, the study's authors say. And whether the coffee is caffeinated or not doesn't matter, they add — the benefits were realized even if the men drank decaf. And women who drink coffee may see some protection against breast cancer, Kotz says. A team of Swedish researchers recently reported that women who drink five or more cups of coffee per day had about a 55 percent lower risk of developing a less common type of breast cancer that doesn't depend on estrogen, compared with women who only drink one cup per day.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.